Joint (NASDAQ:JYNT – Get Free Report) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday.
Separately, Roth Mkm dropped their target price on shares of Joint from $16.00 to $15.00 and set a “buy” rating for the company in a report on Friday, November 8th.
Read Our Latest Stock Report on JYNT
Joint Stock Down 1.4 %
Institutional Trading of Joint
Institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. raised its stake in Joint by 8.9% in the first quarter. Russell Investments Group Ltd. now owns 90,147 shares of the company’s stock worth $1,177,000 after buying an additional 7,375 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in Joint by 5.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 17,464 shares of the company’s stock worth $229,000 after buying an additional 837 shares in the last quarter. Ancora Advisors LLC raised its stake in Joint by 105.0% in the first quarter. Ancora Advisors LLC now owns 99,212 shares of the company’s stock worth $1,296,000 after buying an additional 50,815 shares in the last quarter. Avondale Wealth Management raised its stake in Joint by 15.8% in the second quarter. Avondale Wealth Management now owns 22,000 shares of the company’s stock worth $309,000 after buying an additional 3,000 shares in the last quarter. Finally, Los Angeles Capital Management LLC bought a new position in Joint in the second quarter worth about $1,115,000. 76.88% of the stock is currently owned by hedge funds and other institutional investors.
Joint Company Profile
The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.
Read More
- Five stocks we like better than Joint
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- 3 REITs to Buy and Hold for the Long Term
- Time to Load Up on Home Builders?
Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.